Improvement of Regressive Autism Symptoms in a Child with TMLHE Deficiency Following Carnitine Supplementation
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Issue 111 Special Needs
Issue 111 INSIDE THIS ISSUE Bureau of Community and Special Needs Health Systems From the Division Direc- Child Care Licensing Division tor ................................... 1 www.michigan.gov/michildcare Social Emotional Skills .. 2 (866) 685-0006 Working with Children with Attention Deficit Disorder ......................... 3 Autism 101 ...................... 4 Children with Sensory Processing Disorder ....... 5 From My World to Your Classroom or Home ....... 8 Developmentally Appro- priate Behaviors and Ex- pectations ....................... 9 ADA……….………………..14 FROM THE DIVISION DIRECTOR 2018 is coming to a close very rapidly from Child Care Licensing’s point of view. You have been constantly emailed, sent list serve notices, called or mailed information about the changes we were implementing in 2018. Thanks for your patience as we all went through all of the changes! Background check implementation journey in 2018: • Since March 28th until today we have processed over 77,900 fingerprints of staff, household members and licensees in Michigan. Remember we had no idea how many people worked in child care when we started. The state has paid for almost $3 million dollars of background checks for the child care provid- ers. • The updated PA116 of 1973 finally passed in December of 2017 and went into effect March 28, 2018. We are processing the rule changes currently. • Our in-person trainings were carried out to thousands of child care staff across the entire state over the past 12 months • Our backlog of fingerprints were at over 16,000 just a couple of months ago and today we are down to less than 190. This reduction will allow hiring to be processed much faster for providers employers. -
A Common X-Linked Inborn Error of Carnitine Biosynthesis May Be a Risk Factor for Nondysmorphic Autism
A common X-linked inborn error of carnitine biosynthesis may be a risk factor for nondysmorphic autism Patrícia B. S. Celestino-Sopera,1, Sara Violanteb,c,1, Emily L. Crawfordd, Rui Luoe, Anath C. Lionelf, Elsa Delabyg, Guiqing Caih, Bekim Sadikovica, Kwanghyuk Leea, Charlene Loa, Kun Gaoe, Richard E. Persona, Timothy J. Mossa, Jennifer R. Germana, Ni Huangi, Marwan Shinawia,j,2, Diane Treadwell-Deeringj,k, Peter Szatmaril, Wendy Robertsm, Bridget Fernandezn, Richard J. Schroero, Roger E. Stevensono, Joseph D. Buxbaumh, Catalina Betancurg, Stephen W. Schererf,m, Stephan J. Sandersp, Daniel H. Geschwinde, James S. Sutcliffed, Matthew E. Hurlesi, Ronald J. A. Wandersb, Chad A. Shawa, Suzanne M. Leala, Edwin H. Cook, Jr.q, Robin P. Goin-Kochela,j,r, Frédéric M. Vazb,1, and Arthur L. Beaudeta,j,r,1,3 Departments of aMolecular and Human Genetics, kPsychiatry, and rPediatrics, Baylor College of Medicine, Houston, TX 77030; jTexas Children’s Hospital, Houston, TX 77030; bLaboratory Genetic Metabolic Disease, Departments of Clinical Chemistry and Pediatrics, Academic Medical Center, University of Amsterdam, 1105 AZ, Amsterdam, The Netherlands; cMetabolism and Genetics Group, Research Institute for Medicines and Pharmaceutical Sciences (iMed.UL), Faculdade de Farmácia, Universidade de Lisboa, 1649-003 Lisbon, Portugal; dDepartment of Molecular Physiology and Biophysics, Center for Molecular Neuroscience, Vanderbilt University, Nashville, TN 37232; eDepartment of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, -
The Capacity of Long-Term in Vitro Proliferation of Acute Myeloid
The Capacity of Long-Term in Vitro Proliferation of Acute Myeloid Leukemia Cells Supported Only by Exogenous Cytokines Is Associated with a Patient Subset with Adverse Outcome Annette K. Brenner, Elise Aasebø, Maria Hernandez-Valladares, Frode Selheim, Frode Berven, Ida-Sofie Grønningsæter, Sushma Bartaula-Brevik and Øystein Bruserud Supplementary Material S2 of S31 Table S1. Detailed information about the 68 AML patients included in the study. # of blasts Viability Proliferation Cytokine Viable cells Change in ID Gender Age Etiology FAB Cytogenetics Mutations CD34 Colonies (109/L) (%) 48 h (cpm) secretion (106) 5 weeks phenotype 1 M 42 de novo 241 M2 normal Flt3 pos 31.0 3848 low 0.24 7 yes 2 M 82 MF 12.4 M2 t(9;22) wt pos 81.6 74,686 low 1.43 969 yes 3 F 49 CML/relapse 149 M2 complex n.d. pos 26.2 3472 low 0.08 n.d. no 4 M 33 de novo 62.0 M2 normal wt pos 67.5 6206 low 0.08 6.5 no 5 M 71 relapse 91.0 M4 normal NPM1 pos 63.5 21,331 low 0.17 n.d. yes 6 M 83 de novo 109 M1 n.d. wt pos 19.1 8764 low 1.65 693 no 7 F 77 MDS 26.4 M1 normal wt pos 89.4 53,799 high 3.43 2746 no 8 M 46 de novo 26.9 M1 normal NPM1 n.d. n.d. 3472 low 1.56 n.d. no 9 M 68 MF 50.8 M4 normal D835 pos 69.4 1640 low 0.08 n.d. -
Integrating Treatment for Autism Spectrum Disorders Through the Life Cycle
Integrating Treatment for Autism Spectrum Disorders Through the Life Cycle Robert L Hendren, DO Professor of Psychiatry and Behavioral Science Idaho Autism Summit November 2, 2019 Faculty Disclosure • Grants — Curemark, Roche, Otsuka • Advisory Board — Curemark, BioMarin, Janssen, Axial Biotherapeutics • Honoraria/Royalties: Oxford University Press, Taylor & Francis • Dr. Hendren does intend to discuss the use of off- label/unapproved use of drugs Learning Objectives • Identify successes and challenges in the developmental progression through the life cycle for people with developmental disabilities and their families • Identify and effectively treat comorbid medical, emotional and behavioral symptoms associated with autism spectrum disorders (ASD) • Consider integrating biomedical treatments for ASD including conventional psychotropic medication and what has been referred to as CAM/CIM into a comprehensive program. 2010 1 in 68; 2014 1 in 59 CDC Prevalence of Autism • Possible explanations include – Diagnostic expansion and substitution – Better reporting – Increased recognition – Increasing acceptability – Immigration for services – Environmental toxins – Infectious and immune vulnerability – Epigenetic processes Rutter M. Acta Pediatr. 2005;94(1):2-15. Centers for Disease Control and Prevention. Autism Spectrum Disorders. www.cdc.gov/ncbddd/autism. Accessed June 16, 2015. Hagerman R, Hendren RL (Eds). Treatment of Neurodevelopmental Disorders: Targeting Neurobiological Mechanisms. Oxford University Press; 2014. ASD Genetic Etiology (Levels 1 & 2) • Multiple genes: NRXN12q, 7q11.23, 15q11-13, 16p11.2, SHANK 3, 2, NLGN4, MTHFR 677>T, SEMA5A, 2Q22.1, GRIN2B, 5P14.1, CDH9, 10, FRX, PTEN • Identical twins: 60% to 90% – Fraternal twins: 0% to 36% – Siblings: 4% to 19% • Clear genetic etiology accounts for 25% of autism cases • Hundreds of genetic mutations, some de novo, lead to many ways to develop and treat autism • Is Precision Medicine Possible? Weiss KM, Issues Science and Technology in 2017 Levy D, et al. -
Regressive Autism: a Study in Early Developmental Patterns Rebekah L
Southern Illinois University Carbondale OpenSIUC Research Papers Graduate School 5-2014 Regressive Autism: A Study In Early Developmental Patterns Rebekah L. Brewer Southern Illinois University Carbondale, [email protected] Follow this and additional works at: http://opensiuc.lib.siu.edu/gs_rp Recommended Citation Brewer, Rebekah L., "Regressive Autism: A Study In Early Developmental Patterns" (2014). Research Papers. Paper 465. http://opensiuc.lib.siu.edu/gs_rp/465 This Article is brought to you for free and open access by the Graduate School at OpenSIUC. It has been accepted for inclusion in Research Papers by an authorized administrator of OpenSIUC. For more information, please contact [email protected]. i REGRESSIVE AUTISM: A STUDY IN EARLY DEVELOPMENTAL PATTERNS by Rebekah L. Brewer B.S., Southern Illinois University, 2012 A Research Paper Submitted in Partial Fulfillment of the Requirements for the M.S. Communication Disorders & Science. Rehabilitation Institution In the Graduate School Southern Illinois University Carbondale May 2014 RESEARCH PAPER APPROVAL REGRESSIVE AUTISM: A STUDY IN EARLY DEVELOPMENTAL PATTERNS By Rebekah L. Brewer A Research Paper Submitted in Partial Fulfillment of the Requirements for the Degree of Master of Science in the field of Communication Disorders & Science Approved by: Valerie Boyer, Ph.D., CCC-SLP Kirsten Schaper, M.S., CCC-SLP Graduate School Southern Illinois University Carbondale November 11, 2013 TABLE OF CONTENTS CONTENT PAGE Introduction ................................................................................................... -
Medical Comorbidities in Autism Spectrum Disorders
TA-ESPA-ATP PAPER 2014 1st draft_Layout 1 21/07/2014 19:21 Page 1 Medical Comorbidities in Autism Spectrum Disorders A Primer for Health Care Professionals and Policy Makers Second Edition: July 2014 Prepared by: l Treating Autism l ESPA Research l Autism Treatment Plus TA-ESPA-ATP PAPER 2014 1st draft_Layout 1 21/07/2014 19:21 Page 2 Treating Autism , a charity run entirely by volunteers, provides information and support to families and individuals affected by autism with the aim of improving their quality of life. Registered Charity: www.treatingautism.co.uk No. 1113628, Limited Company Registered in England: No. 5594787. ESPA Research is a not-for-profit subsidiary of ESPA (Education and Services for People with Autism) dedicated to undertaking high-quality research into autism and related conditions all for the public benefit. www.espa-research.org.uk ESPA Research Ltd. Company registration: 6862992. ESPA Registered Charity No. 1037868 | Company No. 2909953 Autism Treatment Plus, dedicated to helping individuals with autism reach optimal health and learning, provides access to diagnostic, medical and behavioural services. www.autismtreatment.org.uk. Limited company registered in England: No. 08623707. © Treating Autism Publications, 2014 Second edition, published July 2014. (First edition published March 2013). All rights reserved. Reproduction of this report, in its entirety and unaltered, by photocopying or electronic means for noncommercial purposes is permitted. Otherwise, no part of this report may be reproduced, adapted, stored in a retrieval system or transmitted by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of Treating Autism Publications. ISBN: 978-0-9575787-2-2 A pdf version of this publication is available from the Treating Autism website www.treatingautism.co.uk. -
How Different Is Early-Onset Childhood Disintegrative Disorder from Autistic Disorder with Speech Loss?*
Open Journal of Psychiatry, 2013, 3, 39-45 OJPsych http://dx.doi.org/10.4236/ojpsych.2013.32A007 Published Online April 2013 (http://www.scirp.org/journal/ojpsych/) How different is early-onset childhood disintegrative * disorder from autistic disorder with speech loss? Hiroshi Kurita1,2#, Kanna Inoue3 1Department of Child Psychiatry, Zenkoku Ryoiku Sodan Center, Tokyo, Japan 2Department of Mental Health, Graduate School of Medicine, Tokyo University, Tokyo, Japan 3Department of Child Psychiatry, Nerima Welfare Center for Handicapped Persons, Tokyo, Japan Email: #[email protected] Received 27 February 2013; revised 30 March 2013; accepted 9 April 2013 Copyright © 2013 Hiroshi Kurita, Kanna Inoue. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Diagnosis; Regression To examine the difference between early-onset (< age 3) childhood disintegrative disorder (CDD) and au- 1. INTRODUCTION tistic disorder with speech loss (ADSL), 8 children Childhood disintegrative disorder (CDD) originates from with early-onset CDD (mean age = 7.6 years, SD = 3.8; Dementia infantilis first reported by Heller [1] in 1908 in 6 males) were compared with 92 age and gender-ratio six infants who had displayed profound mental regres- comparable children with ADSL (mean age = 6.8 sion during the third and fourth years of life. CDD is a years, SD = 4.1; 70 males) on 24 variables not directly subtype of pervasive developmental disorders (PDDs) in related to the key features of CDD (regression after DSM-IV [2] and ICD-10 [3], using similar diagnostic normal development for at least the first 2 years after criteria. -
Downloaded from the App Store and Nucleobase, Nucleotide and Nucleic Acid Metabolism 7 Google Play
Hoytema van Konijnenburg et al. Orphanet J Rare Dis (2021) 16:170 https://doi.org/10.1186/s13023-021-01727-2 REVIEW Open Access Treatable inherited metabolic disorders causing intellectual disability: 2021 review and digital app Eva M. M. Hoytema van Konijnenburg1†, Saskia B. Wortmann2,3,4†, Marina J. Koelewijn2, Laura A. Tseng1,4, Roderick Houben6, Sylvia Stöckler‑Ipsiroglu5, Carlos R. Ferreira7 and Clara D. M. van Karnebeek1,2,4,8* Abstract Background: The Treatable ID App was created in 2012 as digital tool to improve early recognition and intervention for treatable inherited metabolic disorders (IMDs) presenting with global developmental delay and intellectual disabil‑ ity (collectively ‘treatable IDs’). Our aim is to update the 2012 review on treatable IDs and App to capture the advances made in the identifcation of new IMDs along with increased pathophysiological insights catalyzing therapeutic development and implementation. Methods: Two independent reviewers queried PubMed, OMIM and Orphanet databases to reassess all previously included disorders and therapies and to identify all reports on Treatable IDs published between 2012 and 2021. These were included if listed in the International Classifcation of IMDs (ICIMD) and presenting with ID as a major feature, and if published evidence for a therapeutic intervention improving ID primary and/or secondary outcomes is avail‑ able. Data on clinical symptoms, diagnostic testing, treatment strategies, efects on outcomes, and evidence levels were extracted and evaluated by the reviewers and external experts. The generated knowledge was translated into a diagnostic algorithm and updated version of the App with novel features. Results: Our review identifed 116 treatable IDs (139 genes), of which 44 newly identifed, belonging to 17 ICIMD categories. -
Is There a 'Regressive Phenotype' of Autism Spectrum Disorder Associated with the Measles-Mumps-Rubella Vaccine?
Journal of Autism and Developmental Disorders, Vol. 36, No. 3, April 2006 (Ó 2006) DOI 10.1007/s10803-005-0070-1 Published Online: April 28, 2006 Is There a ‘Regressive Phenotype’ of Autism Spectrum Disorder Associated with the Measles-Mumps-Rubella Vaccine? A CPEA Study Jennifer Richler,1 Rhiannon Luyster,1 Susan Risi,1 Wan-Ling Hsu,1 Geraldine Dawson,2 Raphael Bernier,2 Michelle Dunn,3 Susan Hepburn,4 Susan L. Hyman,5 William M. McMahon,6 Julie Goudie-Nice,6 Nancy Minshew,7 Sally Rogers,8 Marian Sigman,9 M. Anne Spence,10 Wendy A. Goldberg,10 Helen Tager-Flusberg,11 Fred R. Volkmar,12 and Catherine Lord13 A multi-site study of 351 children with Autism Spectrum Disorders (ASD) and 31 typically developing children used caregiver interviews to describe the children’s early acquisition and loss of social-communication milestones. For the majority of children with ASD who had experienced a regression, pre-loss development was clearly atypical. Children who had lost skills also showed slightly poorer outcomes in verbal IQ and social reciprocity, a later mean age of onset of autistic symptoms, and more gastrointestinal symptoms than children with ASD and no regression. There was no evidence that onset of autistic symptoms or of regression was related to measles-mumps-rubella vaccination. The implications of these findings for the existence of a ‘regressive phenotype’ of ASD are discussed. KEY WORDS: Autism spectrum disorder; language development; regression; Autism Diagnostic Interview - Revised (ADI-R); measles-mumps-rubella (MMR) vaccine; gastrointestinal disorders. While most children with Autism Spectrum Dis- orders (ASD) are described as showing developmental differences from birth or early in infancy, a substantial 1 University of Michigan, Ann Arbor, USA. -
Potential Role of L-Carnitine in Autism Spectrum Disorder
Journal of Clinical Medicine Review Potential Role of L-Carnitine in Autism Spectrum Disorder Alina K˛epka 1,† , Agnieszka Ochoci ´nska 1,*,† , Sylwia Chojnowska 2 , Małgorzata Borzym-Kluczyk 3, Ewa Skorupa 1, Małgorzata Kna´s 2 and Napoleon Waszkiewicz 4 1 Department of Biochemistry, Radioimmunology and Experimental Medicine, The Children’s Memorial Health Institute, 04-730 Warsaw, Poland; [email protected] (A.K.); [email protected] (E.S.) 2 Faculty of Health Sciences, Lomza State University of Applied Sciences, 18-400 Lomza, Poland; [email protected] (S.C.); [email protected] (M.K.) 3 Department of Pharmaceutical Biochemistry, Medical University of Bialystok, 15-089 Bialystok, Poland; [email protected] 4 Department of Psychiatry, Medical University of Bialystok, 15-089 Bialystok, Poland; [email protected] * Correspondence: [email protected]; Tel.: +48-22-815-73-01 † These authors are sharing the first place. Both contributed equally to this work. Abstract: L-carnitine plays an important role in the functioning of the central nervous system, and especially in the mitochondrial metabolism of fatty acids. Altered carnitine metabolism, abnormal fatty acid metabolism in patients with autism spectrum disorder (ASD) has been documented. ASD is a complex heterogeneous neurodevelopmental condition that is usually diagnosed in early child- hood. Patients with ASD require careful classification as this heterogeneous clinical category may include patients with an intellectual disability or high functioning, epilepsy, language impairments, or associated Mendelian genetic conditions. L-carnitine participates in the long-chain oxidation of fatty acids in the brain, stimulates acetylcholine synthesis (donor of the acyl groups), stimulates ex- pression of growth-associated protein-43, prevents cell apoptosis and neuron damage and stimulates Citation: K˛epka,A.; Ochoci´nska,A.; neurotransmission. -
Non-Recurrent MECP2 Duplications Mediated by Genomic Architecture-Driven
Downloaded from genome.cshlp.org on October 4, 2021 - Published by Cold Spring Harbor Laboratory Press 1 Non-recurrent MECP2 duplications mediated by genomic architecture-driven DNA breaks and break-induced replication repair Running title: Genomics of MECP2 duplications Marijke Bauters,1,2,1 Hilde Van Esch,3,1 Michael %. Frie(,4 Odile Boespflug- ,anguy,5 Martin .enker,6 Angela M. Vianna-Morgante,0 1arla 2osenberg,0 %aakko Ignatius,8 Martine 2aynaud,5 6aren Hollanders,1,2 6aren 7ovaerts,1,2 6ris Vandenreijt,1,2 Florence Niel,5 8ierre Blanc,5 2oger E. Stevenson,4 %ean-8ierre Fryns,3 8eter Marynen,1,2 1harles E. Schwart(,4 and 7uy Froyen1,2,11 1Human Genome Laboratory, Dept. for Molecular and Developmental Genetics, IB, Leuven, Belgium$ 2Human Genome Laboratory, Dept. of Human Genetics, %.U.Leuven, Leuven, Belgium$ 3Dept. of Human Genetics, University Hospital Gasthuisberg, Leuven, Belgium$ 4JC Self ,esearch Institute of Human Genetics, Greenwood Genetic Center, Greenwood, SC$ .Centre Hospitalier Universitaire, Clermont-0D, G1n1ti2ue Humaine, Clermont-0errand, 0rance$ 3Institute of Human Genetics, University of Erlangen- Nuremberg, Erlangen, Germany$ 7Dept. Genetics and Evolutionary Biology, Institute of Biosciences, University of S6o Paulo, Bra7il$ 8Dept. Clinical Genetics, Oulu University Hospital and Oulu University, 0inland$ 9Centre Hospitalier Universitaire de Tours, Service de G1n1ti2ue, Tours, 0rance Ke words: MECP2, duplication, recombination model, breakpoint anal sis 1 ,hese two authors contributed equally to this work. Bauters_ms4.doc 14-3-2008 Downloaded from genome.cshlp.org on October 4, 2021 - Published by Cold Spring Harbor Laboratory Press 2 111orresponding author. E-mail guy.froyen@ med.kuleuven.be; fax: +32-16-340166 Address for correspondence: Dr. -
2012 Portfolio Analysis Projects: Question 2: How Can I Understand
2012 Portfolio Analysis Projects Please note that data are not yet final; additional projects may be added. QUESTION 2: HOW CAN I UNDERSTAND WHAT IS HAPPENING? 2.S.A Support at least four research projects to identify mechanisms of fever, metabolic and/or immune system interactions with the central nervous system that may influence ASD during prenatal-postnatal life by 2010. IACC Recommended Budget: $9,800,000 over 4 years. (Fever studies to be started by 2012.) Principal Project Title Institution Funding Funder Investigator Systematic characterization of the Alaedini, Weill Cornell Medical $0.00 Department immune response to gluten and Armin College of Defense casein in autism spectrum disorders Autoimmunity against novel antigens Balice- University of $320,000. National in neuropsychiatric dysfunction Gordon, Pennsylvania 00 Institutes of Rita Health Convergence of immune and genetic Barrow, University of $0.00 Brain & signaling pathways in autism and Stephanie California, Davis Behavior schizophrenia Research Foundation Altered placental tryptophan Bonnin, University of $535,699. Department metabolism: A crucial molecular Alexandre Southern California 00 of Defense pathway for the fetal programming of neurodevelopmental disorders Brain mitochondrial abnormalities in Chauhan, New York State $20,000.0 Autism autism Abha Institute for Basic 0 Research Research in Institute Developmental Disabilities Mechanisms of synaptic alterations in Dunaevsky University of $579,882. Department a neuroinflammation model of autism , Anna Nebraska Medical